Whole Genome Sequencing for Rare Disorders: The Future Is Here

Join MitoAction , Christine Stanley, Chief Director of Clinical Genomics at Variantyx and David Keane, Director of Rare Disorders at Variantyx, Inc. for our Monthly Mito Expert Series presentation titled Whole Genome Sequencing for Rare Disorders: The Future Is Here on Friday, April 9, 2021.

About the Speakers:

Christine Stanley, PhD, FACMG, is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory. Prior to joining Variantyx, Christine held positions as Head of Clinical Laboratory at WuXi NextCODE, Chief Director of Clinical Genomics at Courtagen Life Sciences and Genetics Director at Athena Diagnostics. She maintains a part-time appointment as Clinical Laboratory Director of QnA Diagnostics.

Christine holds a Bachelor’s degree in Genetics from Texas A&M University and a PhD in Human Genetics from the Medical College of Virginia with fellowship training at Boston University in clinical molecular genetics. She is a diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.

David Keane has been involved with Neurogenetics since 1998 when he started working for Athena Diagnostics. He has attended over 50 Mitochondrial Disease Grand Rounds Presentations by Dr. Bruce Cohen, Sumit Parikh, Fran Kendall, Amy Goldstein, among others. David was hired by GeneDx in 2011 to help build the Neurogenetics team and currently serves as Director for Rare Disorders for Variantyx.